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ABSTRACT
Background The cystic ﬁbrosis (CF) basic defect, caused
by dysfunction of the apical chloride channel CFTR in the
gastrointestinal and respiratory tract epithelia, has not
been employed so far to support the role of CF modiﬁer
genes.
Methods Patients were selected from 101 families with
a total of 171 F508del-CFTR homozygous CF patients to
identify CF modifying genes. A candidate gene based
association study of 52 genes on 16 different
chromosomes with a total of 182 genetic markers was
performed. Differences in haplotype and/or diplotype
distribution between case and reference CF
subpopulations were analysed.
Results Variants at immunologically relevant genes
were associated with the manifestation of the CF basic
defect (0.01<Praw<0.0001 at IL1B, TLR9, TNFa, CD95,
STAT3 and TNFR). The intragenic background of F508del-
CFTR chromosomes determined disease severity and
manifestation of the basic defect (Praw¼0.0009). Allele
distributions comparing transmitted and non-transmitted
alleles were distorted at several loci unlinked to CFTR.
Conclusions The inherited capabilities of the innate and
adaptive immune system determine the manifestation of
the CF basic defect. Variants on F508del-CFTR
chromosomes contribute to the observed patient-to-
patient variability among F508del-CFTR homozygotes. A
survivor effect, manifesting as a transmission
disequilibrium at many loci, is consistent with the
improvement of clinical care over the last decades,
resulting in a depletion of risk alleles at modiﬁer genes.
Awareness of non-genetic factors such as improvement
of patient care over time is crucial for the interpretation
of CF modiﬁer studies.
INTRODUCTION
Cystic ﬁbrosis (CF) is the most common severe,
monogenic, autosomal recessively inherited disease,
affecting 1 out of 3200 newborns in the Caucasian
population.
1 The manifestation of the multiorgan
disease varies among individuals and even among
siblings homozygous for the most frequent disease-
causing lesion F508del-CFTR.
2e4 Improvement of
medical care throughout the last decades has
increasedthepatient’slifeexpectancyfromlessthan
5 years in the 1940s to 37 years estimated for the
current CF population,
56demonstrating convinc-
ingly that mainly non-genetic factors determine the
disease outcome. Hallmarks of improved symptom-
atictherapyaretheuseofantibioticsandnutritional
repletionincentresspecialisedforCFcare,startingin
the mid-1950s,
5 and the development of specialised
drugs such as novel pancreatic enzymes or
recombinant DNAse since the late 1980s.
5 Centre to
centrevariationsinqualityofcare
7andtheinﬂuence
of socioeconomic status on the course of CF disease
6
furthermore emphasise the inﬂuence of non-
inherited factors on disease manifestation. Conse-
quently, attempts to uncover clinically meaningful
modiﬁergenesrequirethatnon-genetic confounding
factors are taken into account.
The basic defect in CF is deﬁned as an impaired
chloride conductance in epithelia that express
CFTR, a chloride channel localised in the apical
membrane of differentiated epithelial cells.
1 Nasal
potential difference measurement (NPD) and
intestinal current measurement (ICM) allow the
assessment of the CF basic defect in the two major
affected organ systems in CFdthe respiratory tract
and gastrointestinal tract.
89Even though the
manifestation of the basic defect on the cellular and
epithelial level is less vulnerable to environmental
inﬂuences than any clinical outcome parameter
such as lung function, growth and stature,
substantial variability of the basic defect phenotype
among sib pairs with shared CFTR mutation
genotype is observed.
10 11 We hypothesise that CF
genetic modiﬁers can be recognised through
a genotypeephenotype association with the basic
defect.
If the inﬂuence of modulating genes on the CF
phenotype is at the core of interest, the power of
the study to detect a modifying gene will increase,
with the standardisation of the CFTR mutation
genotype
1 25and environmental inﬂuences
15 e7 as
the two major confounding variables of CF disease
severity. While the high frequency of the F508del-
CFTR allele among Caucasians
12allows the
recruitment of a sufﬁcient number of patients who
are homozygous for the same CFTR disease-causing
lesion,
31 21 3standardisation of the environment
cannot be achieved for a human study population.
Hence, the best choice are twin and sibling patient
pairs to minimise many environmental effects as
siblings will share their family environment, visit
the same physician and be treated at the same CF
centre. Monozygous twins, being genetically iden-
tical, and dizygous patient pairs, sharing half of
< Supplementary material and
tables are published online only.
To view these ﬁles please visit
the journal online (http://jmg.
bmj.com).
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Original articletheir genome, can be compared to deduce the inﬂuence of
inherited factors on the phenotype.
14
The European Cystic Fibrosis Twin and Sibling Study
Consortium
3 has collected clinical data on more than 500 CF
twin and sibling pairs. We have previously reported how infor-
mative patient pairs with extreme phenotypes can be selected
from this cohort for candidate gene analysis
3 and described CF
modiﬁer genes on six chromosomes.
15e22 In this study, our
objectives are: (1) to qualify the relative impact of the CFTR
gene, environmental and other inherited factors on CF disease
severity; (2) to identify genetic modiﬁers for the CF basic defect;
and (3) to observe whether or not these are the same genes that
modify CF disease severity. We have tested a total of 182 genetic
markers targeting 52 candidate gene loci on 16 different chro-
mosomes for their association with CF disease severity and the
manifestation of the CFTR mediated basic defect, by genotyping
a cohort composed of 101 families with a total of 171 F508del-
CFTR homozygous patients. Among these are 12 genes studied
as CF modiﬁers by others,
12 13 23e26 26 additional genes which
represent plausible modiﬁer candidates such as direct interaction
partners of CFTR, alternative ion channels and components of
the innate immune system, and 14 candidate genes which were
selected by transcriptome analysis comparing intestinal epithe-
lial biopsies of controls and CF patients. To our knowledge, this
is the only study on CF modiﬁers that combines the powerful
approach to analyse affected sib pairs
13 while at the same time
exploiting the phenotypic contrast between informative
extreme clinical phenotypes.
12
METHODS
Patients and phenotypes
This study reports on clinical data from 466 twin and sibling
pairs and genetic data from 101 CF families, 85 of which are
a subgroup of the twin and sibling study cohort. Enrolment of
patient pairs into the association study was based on one of the
following criteria: the twin or sibling pair exhibits an extreme
clinical phenotype
3 and/or the patient was characterised for the
CF basic defect.
10 11 Sixteen unrelated F508del-CFTR homozy-
gotes from the CF clinic in Hannover were included who
participated in an analysis of the basic defect and transcriptome
in the intestine to deﬁne 14 candidate genes (van Barneveld et al,
2010, unpublished data).
We selected the 12% most informative pairs from the entire
sample of 318 CF twin and sibling pairs by a ranking algorithm
3
that relies on two clinical parameters most sensitive for course
and prognosis of CF.
27 28 These 37 dizygous F508del-CFTR
homozygous patient pairs, enrolled due to their contrasting
extreme clinical phenotype (Figure 1), were comparable with
respect to their birth cohort.
18
CF basic defect phenotypes derived from intestinal current
measurement (ICM) and nasal potential difference measure-
ment (NPD) were obtained for 71 patient pairs.
10 11 Brieﬂy,
secretagogues that activate or block ion channels, ion
exchangers or components of the cellular signal transduction
pathways were applied by superfusion of the surface of the
lower nasal turbinate
9 or to excised rectal suction biopsies
mounted in a micro-Ussing chamber
8 using a ﬁxed sequence of
deﬁned pharmacologically active substances.
Based on the sib pairs’ clinical phenotype and the individual’s
manifestation of the CF basic defect, subgroups were deﬁned as
cases and references for an association study (ﬁgure 1). These
subgroups are by deﬁnition partially (clinical phenotype vs ICM)
or nearly completely (ICM and NPD phenotypes) overlapping
sets of patient pairs (see supplementary material for details).
This study was approved by the ethics committee of the
Medizinische Hochschule Hannover. Written informed consent
was obtained from all participants or their parental guides.
Candidate genes and genetic markers
Genotypes of two indels, 101 single nucleotide polymorphisms
(SNPs) and 79 microsatellites were analysed for this study.
Seventy-three markers were developed de novo for this study,
building on raw genomic sequences containing microsatellite
repeats within or near the targeted candidate gene to develop
polyallelic markers (40 microsatellites) or on the public SNP
database (33 diallelic markers). To compensate for the loss of
power inﬂicted upon the study by the limited sample size of
subgroups stratiﬁed for extreme clinical phenotypes (being
infrequent by deﬁnition) or for basic defect phenotypes such as
F508del-CFTR homozygotes who display CFTR mediated
residual function (being infrequent due to the aetiology of the
disease), care was taken to include only informative markers in
the study: between one and 13 microsatellite motifs (median:
four motifs) were tested per candidate gene locus to obtain one
marker with a suitable polymorphism information content of
0.61e0.91 (mean 0.76) per targeted candidate gene. SNP markers
were preselected based on HAPMAP data.
29 Technical details on
all markers and genotyping methods are provided in the
supplementary material.
Genetic modelling
Genetic modelling was done with the LISREL8 software
package.
30 Brieﬂy, covariance matrices from standard normal
distributions derived from weight for height and forced expira-
tory volume in 1 s as percentage of predicted value (FEV1%pred)
data were used to ﬁt a model taking genetic effects as well as
random and shared environmental effects into account. Appli-
cability of the model was judged by the Aikaike information
criterion.
30
Association study
Genetic data for the association study was evaluated using the
FAMHAP software package
31 which allows family based anal-
ysis
32 33 and accepts data evaluation in association studies on
unrelated individuals as well as on affected sib pairs.
31 All
caseereference comparisons were carried out using 10.000
Monte-Carlo simulated datasets.
31e33 Nuclear families were
analysed by the transmissionedisequilibrium test (TDT)
34
extended to both nuclear families with more than one affected
child and to multi-marker haplotypes.
31e33 To allow a compa-
rable assignment of weighted haplotype explanations, the entire
genotyping data were provided as training set to FAMHAP for
all case-reference comparisons.
All candidate genes were analysed for an underrepresentation
of alleles among transmitted chromosomes (TDT) as well as by
caseereference comparisons for their association with disease
severity (two caseereference comparisons), ICM (two casee
reference comparisons) or NPD (three caseereference compari-
sons). Assignment of case and reference status is outlined in
ﬁgure 1 and detailed in the supplementary material. To conﬁrm
observed associations, we have employed within-dataset vali-
dation strategies using partial replicates as detailed in the
supplementary material. Signiﬁcance within the entire dataset
of 182 markers was conservatively judged by Bonferroni
correction for 200 independent markers (threshold Praw¼3310
-4
for a¼0.05) or 52 independent loci (threshold Praw¼9310
-4 for
a¼0.05).
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Original articleFigure 1 Assembly of patient subsets
for genetic modelling and association
study. Weight, height, and lung function
data of at least one out of two siblings
was received in 1995e1996 for 540
cystic ﬁbrosis (CF) sib pairs from 158 CF
clinics in 14 European countries. Pairs
for whom clinical data was obtained for
both sibs of a pair were included into
genetic modelling (466 pairs withweight
andheight,318pairswithlungfunction).
3
Subsamples of F508del homozygotes
were selected for the association study
based on the clinical phenotype or the
basic defect phenotype which was
measured by nasal potential difference
measurement (NPD) and intestinal
current measurement (ICM).
10 11 In total,
171 patients from 101 families were
genotyped. Two patients with CFTR
mutation genotypes other than
F508del/F508del were only included for
the phenotype ‘DIDS-sensitive chloride
conductance’ determined by ICM. The
association study compared subsets of
affected patient pairs in their
manifestation of the clinical phenotype,
and correspondingly only dizygous
pairs were included. In case of
caseecontrol comparisons of the basic
defect in subsamples of unrelated
index cases, one twin per monozygous
twin pair was added to the cohort. For
the association study on ICM
phenotypes, 16 families with F508del
homozygous offspring recruited from
the CF clinic in Hannover, Germany
were included. Integers within this
ﬁgure correspond to the number of
independent families while all numbers
in brackets refer to the number of
individual patients. Relative proportions
of samples and subsamples stratiﬁed
for extreme phenotypes are displayed
on the basis of the number of
independent nuclear familiesdthat is,
of sib pairs instead of individual patientsdin order to represent sample sizes based on their number of independent genetic contributions which
deﬁne the effective number of chromosomes considered for the genetic association study. Integers on top of diagrams report the sample size as
the sum of all subgroups. Integers adjacent to diagrams report sizes of subgroups which are visualised as slices. For subgroups consisting of
540, 466 and 318 pairs, the entire circle diameter corresponds to the sample size. For subgroups consisting of 46 and 55 families, the sample
size is represented in proportion to the larger datasets by the circle diameter carrying the sample size label (white central circle with red rim on
top of the diagram). Composition of subgroups stratiﬁed for manifestation of the basic defect is displayed on the basis of individual patients. The
numbers displayed for the contrasting phenotypes analysed in the caseecontrol scenarios show the effective sample size, taking into account
that sib pairs who show a discordant basic defect phenotype can contribute to one out of two (NPD phenotypes) or one out of three (ICM
phenotypes) subgroups only in the association study. In other words, subsets of unrelated patients were deﬁned by an index case strategy
whereby extreme basic defect phenotypes were selected for in pairs for whom discordance ICM or NPD was observed. As NPD measurements
were obtained for two siblings of a pair in most cases, two subsets for each caseecontrol test were evaluated to provide an internal control
depending on which sibling was assigned at random to be the index case. Candidate genes were interrogated for their association with disease
severity using the phenotypic contrast between concordant/mildly affected patient pairs, concordant/severely affected patient pairs, and
discordant patient pairs. For this purpose, 37 dizygous pairsdrepresenting the 12% most informative patient pairs of the entire sampledwere
selected based on a non-parametric ranking algorithm as described previously.
3 NPD data were used ﬁrstly to enquire for an association with
sodium transport via the amiloride sensitive proportion of the potential, using the upper and lower 30% of the entire sample to deﬁne extreme
phenotypes, secondly to evaluate an association with residual chloride secretion activated by chloride-free gluconate solution and isoproterenol,
and thirdly to analyse a contribution of the selected candidate genes on ATP stimulated chloride response. The basic defect assessed by ICM
was evaluated using a set of patients devoid of residual chloride secretion as controls. The pleiotropic chloride channel inhibitor DIDS, to which
CFTR is not sensitive at the chosen concentration, was used to discriminate CFTR mediated residual chloride secretion from chloride secretion
mediated by alternative channels which are DIDS sensitive.
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Original articleRESULTS
Inherited, environmental and maternal factors inﬂuence CF
disease manifestation
We have compared intrapair differences in weight expressed as
percentage of predicted weight for height (wfh%) and CF
population centiles for the lung function parameter FEV1%
(FEVPerc) and conducted genetic modelling on 466 (wfh%) and
318 (FEV1%) patient pairs (ﬁgure 2). While monozygous twins
were more concordant in their FEVPerc than either dizygous
twins or sibs, all twins were more concordant than sibs in their
wfh% irrespective of their zygosity status. This indicates that
the shared pre- and early postnatal period which distinguishes
twins from sibs is associated with lower intrapair differences in
wfh% while concordance in lung function is dominated by
genetic factors as only monozygous twins share their entire
genetic information in contrast to dizygous twins or siblings
who have half of their genetic information in common. The
results of the genetic modelling analysis imply that inherited
factors have a larger impact on the patient-to-patient variation
in wfh% than for lung function (ﬁgure 2B). These data are in
accordance with heritability estimates from other CF twin and
sibling cohorts.
4
Association study
Candidate genes were interrogated for their association with
disease severity using the phenotypic contrast between concor-
dant/mildly affected patient pairs, concordant/severely affected
patient pairs, and discordant patient pairs. For this purpose, 37
dizygous pairsdrepresenting the 12% most informative patient
pairs of the entire sampledwere selected based on a non-para-
metric ranking algorithm as described previously.
3 NPD data
were used: ﬁrst, to enquire for an association with sodium
transport via the amiloride sensitive proportion of the potential,
using the upper and lower 30% of the entire sample to deﬁne
extreme phenotypes; secondly, to evaluate an association with
residual chloride secretion activated by chloride-free gluconate
solution and isoproterenol; and thirdly to analyse a contribution
by the selected candidate genes on adenosine triphosphate (ATP)
stimulated chloride response. Basic defect assessed by ICM was
evaluated using a set of patients devoid of residual chloride
secretion as controls. The pleiotropic chloride channel inhibitor
DIDS, to which CFTR is not sensitive, was used to discriminate
CFTR mediated residual chloride secretion from chloride secre-
tion mediated by alternative channels which are DIDS sensi-
tive.
10 11 After correction for multiple testing, signiﬁcance was
retained at the following loci and for the following phenotypes
(ﬁgure 3): 7q31.1/CFTR:P ¼0.0009 (NPD_Na+) and
Praw¼0.0008 (NPD_ATP); 7q34/D7Sat3: Praw¼0.0005 (disease
severity cis); 11q13/GSTP1 Praw¼0.0006 (NPD_ATP); 12p13/
TNFR Praw¼0.0004 (NPD_Gl/Iso) and Praw¼0.0003 (NPD_ATP);
12q13/KRT8 Praw¼0.0004 (ICM_Res); 16p13.3/NHERF2
Praw¼0.0001 (ICM_Res). We have previously reported an asso-
ciation with DIDS-sensitive residual chloride secretion in ICM at
the CLCA-gene cluster
15 and an association with disease severity
for LEP,
16 CD95,
17 TNFR,
18 SCNN1B,
18 SCNN1G,
18 at the
CEACAM gene cluster,
19 20 and at a paternally imprinted gene
on 7q34.
21 Association of these genes with other phenotypes are
reported here for the ﬁrst time.
Informative microsatellite markers allow the assessment of
candidate genes as CF modiﬁers
Most candidate gene association studies in CF rely on the typing
of polymorphisms which are suspected or known to alter the
performance of the gene or its protein product,
12 23 a strategy
that cannot be applied as long as functional variants are
unknown to date. Building on our previous experience,
18 22 we
developed informative microsatellite markers to interrogate
these genes (see supplementary material for details). Results of
the association study are displayed in ﬁgure 3. To conﬁrm initial
ﬁndings by microsatellite markers, a low density SNP scan was
done for PRSS8, KRT8/KRT18, TLR4 and IL1B, and previously
obtained genotyping data
18 was evaluated for basic defect
phenotypes at SCNN1B/SCNN1G and TNFR/SCNN1A. Signif-
icance after correction for multiple testing was retained for the
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Figure 2 Relative impact of environmental and inherited factors on
cystic ﬁbrosis (CF). (A) Distribution of intrapair differences in weight for
height % (wfh%, left) and the CF population centiles for FEV1%pred
(FEVPerc, right) among sib pairs, dizygous twins (DZT) and monozygous
twins (MZT). Overall comparisons were done by Kruskal-Wallis rank test
(wfh%: P¼5310
-6; FEVPerc: P¼0.067) and individual subgroups were
compared by Dunn rank test. Please note that both monozygous and
dizygous twins are similarly concordant in wfh%, indicating that the
shared in utero environment determines outcome in wfh%. In contrast,
monozygous twins are more concordant that either dizygous twins or
sibs in FEVPerc, implying that lung function is inﬂuenced by inherited
factors. (B) Relative impact of inherited and environmental factors on
disease manifestation as estimated by genetic modelling. Covariance
matrices of weight as % of predicted weight for height (WFH) and forced
expiratory volume in 1 s as % of predicted value (LF) were analysed by
genetic modelling.
30 All patient pairs and the subgroup of F508del-CFTR
homozygotes were evaluated. Models were based on a linear
combination of the four following factors: random environmental effects,
shared environmental effects, additive and dominant genetic effects.
Goodness-of-ﬁt was judged by c
2 measure, whereby in case of two or
more models with a similar goodness-of-ﬁt the least complicated model,
based on the fewest out of the four linearly combined factors, was
accepted as suggested by the Akaike information criterion.
30 Consensus
diagrams displaying the impact of inherited (black bars) and
environmental (white bars) factors are shown.
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Original articleassociation of the member of the CFTR network NHERF2 with
DIDS insensitive residual chloride secretion detected by ICM
(Praw¼0.0001, diplotype model; Praw¼0.0007, haplotype model;
Praw<10
-5, accumulation of rare alleles among patients with
residual function; ﬁgure 3 and ﬁgure 4). NHERF2 was interro-
gated with two microsatellite motifs located at a distance of
30 kb and 70 kb. Seven further genes are encoded on the
segment between marker and targeted candidate gene. Even
though none of these can be reasonably associated with CF
pathophysiology, neighbours of the targeted candidate gene
have to be considered; we observed an association of the
response to gluconate and isoproterenol in NPD at the TNFR/
SCNN1A locus (ﬁgure 3). Haplotype analysis of the 12p13 locus
with four intragenic markers for each of the two neighbouring
genes TNFR and SCNN1A revealed that the effect is mediated
by the cytokine receptor TNFR and not by the a subunit of
the amiloride sensitive epithelial sodium channel SCNN1A
(ﬁgure 4).
Diversity of the F508del-CFTR genetic background determines
the clinical variability of F508del-CFTR homozygotes
We have included intragenic and CFTR ﬂanking markers in our
association study. As the enrolled patients are F508del-CFTR
homozygous, the major disease causing variant is identical for all
study subjects. In contrast, these F508del-CFTR chromosomes
differ at closely linked neighbouring SNPs.
35e37 We tested in our
association study whether these different F508del-CFTR alleles
are asymmetrically distributed when comparing mildly and
severely affected patients or subgroups stratiﬁed for the mani-
festation of the basic defect. We observed a signiﬁcant associa-
tion of the CFTR core haplotype to the response of the nasal
epithelium to superfusion with amiloride (Praw¼0.0009; ﬁgure 3
and ﬁgure 4) and ATP (Praw¼0.0008; ﬁgure 3 and ﬁgure 4).
Moderate association of CFTR was observed with CF disease
severity and response to gluconate and isoproterenol in NPD
(0.001<Praw<0.01; ﬁgure 3 and ﬁgure 4). These ﬁndings
demonstrate that the different F508del-CFTR alleles are
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Figure 3 Association of candidate genes with CF disease severity and basic defect. Candidate genes are listed according to their position in the
human genome. Association to genes instead of results of individual markers are displayed if several linked markers were analysed per gene or gene
cluster. For PRSS8, SCNN1B/SCNN1G, KRT8/KRT18, TNFR/SCNN1A, TLR4, the results of the microsatellite scan and the conﬁrmation by low
resolution single nucleotide polymorphism (SNP) typing are shown. Solid lines are used to indicate unlinked genes, adjacent loci within 10 Mb distance
are separated by dotted lines and neighbouring genes are not separated by lines between gene names. All candidate genes were analysed for an
underrepresentation of alleles among transmitted chromosomes (TDT) as well as by caseereference comparisons for their association with disease
severity, intestinal current measurement (ICM) or nasal potential difference measurement (NPD): disease severity cisdcase ¼ concordant mildly
affected patient pairs, reference ¼ concordant severely affected patient pairs
16e18; disease severity transdcase ¼ discordant patient pairs, reference
¼ concordant patient pairs
16 17; ICM_Resdcase ¼ DIDS-insensitive (CFTR-mediated)
10 11 residual chloride secretion, reference ¼ no residual chloride
secretion; ICM_DIDSResdcase-DIDS-sensitive (sCFTR)
10 11 residual chloride secretion, reference ¼ no residual chloride secretion; NPD_Na
+dcase ¼ low response to amiloride, reference ¼ high response to amiloride; NPD_Gl/Isodcase ¼ no response to gluconate and isoproterenol,
reference ¼ residual chloride secretion response to gluconate and isoproterenol; NPD_ATPdcase ¼ no response to ATP, reference ¼ residual
chloride secretion response to ATP. Solid dots correspond to raw P values for single chromosomes (marked H), chromosome pairs (marked D) or
accumulation of rare variants (marked r). All displayed values are uncorrected Praw (see also supplemental table 8).
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Original articlefunctionally non-equivalent. In other words, sequences adjacent
to the F508del-CFTR mutation which are phylogenetically
younger than the F508del variant and/or sequences in the
vicinity of the CFTR gene allowing for allelic diversity among
F508del chromosomes through recombination have a functional
impact on the manifestation of the CF basic defect and disease
severity. We would like to emphasise the point that variant
F508del-CFTR genes (Praw¼0.0009) more than ENaC variants
Figure 4 Comparison of allele
distributions among patients with
different basic defect phenotypes.
Allele distributions are shown for the
CFTR-locus (AeC), SCNN1A, encoding
the a-subunit of the epithelial sodium
channel ENaC and the neighbouring
gene TNFRSF1A, encoding the 55 kDa
receptor for TNFa (TNFR) (D, E) and
the CFTR interaction partner NHERF2
(F). Pictograms represent the relative
location of targeted candidate gene
(black box) and genotyped markers
(vertical lines). Markers are: XV-2c, the
variant HUG16RS
35 and J3.11 (A, B);
XV-2c, KM19 5’ and IVS17bTA
36 (C);
four markers in SCNN1A (nt7AG, SC3,
SC4 and rs2228576 (D); four markers
in TNFR (rs767455, D12S889,
rs1800692 and rs1800693 (E); two
microsatellites near NHERF2 (F).
Alleles at IVS17bTA are calibrated in
accordance with Morral et al.
37 For
other microsatellites, arbitrary repeat
units were assigned with 10
corresponding to the most frequently
observed allele. Single nucleotide
polymorphisms (SNPs) typed by
polymerase chain reaction-restriction
fragment length polymorphism (PCR-
RFLP) are named according to the
presence (allele 2) or absence (allele 1)
of the diagnostic restriction site. P
values and corresponding allele
distributions (AeB; DeF) or diplotypes
distributions (C) are given for six
caseecontrol tests. Pbest is the best
observed P value while Pglobal was
corrected for multiple testing
33 of all
markers at the locus. Phenotypes are:
NPD_Amil: NPD change to amiloride
[mV]; NPD_ATP: NPD change to ATP;
NPD_GI: NPD change to gluconate and
isoproterenol [mV]; ICM no Res.: no
residual response; ICM Res.: cAMP
sensitive and DIDS insensitive residual
chloride secretion. The four-marker
haplotype at TNFR correlates with
cystic ﬁbrosis (CF) disease severity
18
whereby allele 1-10-2-2 is associated
with a mild CF phenotype (E) and is
also overrepresented among patients
exhibiting residual chloride secretion
assessed by nasal potential difference
measurement (NPD) (D).
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Original article(Praw¼0.0695 at locus SCNN1B/SCNN1G;P raw ¼0.0183 at
T663A in SCNN1A) determined the sensitivity of the CF nasal
epithelium to amiloride in our study population (ﬁgure 3).
Host defence capabilities affect the manifestation of the CF
basic defect
We selected cytokines as well as cytokine and pathogen recep-
tors as candidate genes and tested these for an association with
basic defect phenotypes. Minor (0.01<Praw<0.1; TLR5, CD14,
IFNGR1,TLR4,TGFB1),moderate(0.001<Praw<0.01;IL1B,TLR9,
TNFa, CD95, STAT3), and signiﬁcant (0.0001<Praw<0.001;
TNFR) associations of host defence genotype to basic defect
phenotype were observed (ﬁgure 3). As none of these genes
encode ion channels or their intermediate interaction partners,
these genotypeephenotype relations were a priori unantici-
pated. However, crosstalk between the immune system and
secretory properties of epithelial cells have been described
before: for cytokines interleukin 10 (IL10), interferon g (IFNg),
tumour necrosis factor a (TNFa), IL1b, transforming growth
factor b (TGFb), IL4 and IL13, alterations of CFTR and/or
ENaC and/or CaCC expression and/or activity, resulting in
altered ion and ﬂuid transport, have been communicated.
38e41
This has been interpreted as an unspeciﬁc host response to
pathogens as the surface liquid is increased on the epithelium
upon induction of a hypersecretory state by inﬂammatory
stimuli,
39 and consequently mucociliary clearance of the
intruding pathogen will be alleviated. Our data show that the
effect of the host defence system on ion conductance prop-
erties of CF epithelia outweighs the effect of major ion
channels which we also analysed in our association study.
DISCUSSION
Modiﬁer genes have been studied in CF since Zielenski et al
described CFM1 in 1999.
23 Among those studies which analyse
several candidate genes at once, one modiﬁer only is reported.
12 26
On the other hand, negative outcomes in these studies are often
contradicted by other isolated reports (reviewed by Cutting
24)
and genetic modelling has led to the expectation that many more
modiﬁers need to be uncovered in CF.
42 5This ambiguity is likely
to be understood if non-inherited factors,
16which act differently
between CF centres
7 as well as between patients from different
birth cohorts,
5 are taken into account. Improvement of therapy,
quality of life and life expectancy is at the heart of medical care
for all diseases. However, the increase in lifespan among CF
patients within the last decades is outstanding in comparison to
other chronic diseases, signifying that better medication and
improvement of therapeutic management dramatically alter
the environment with which our patients have to cope. As
a consequence, for the human geneticist studying a CF
modiﬁer in a cross-sectionally recruited patient sample, carriers
of high risk alleles will be less frequent, especially among early
born patient cohorts.
20 Consequently, caseecontrol compari-
sons might lack power to detect an allelic imbalance if the
frequency of the risk alleles within the entire CF population is
reduced owing to the survivor effect. If parental genotype
information is available, the allelic bias introduced by
a survivor effect can be visualised by comparing transmitted
and non-transmitted alleles within CF families.
18 In support
of this, many loci reported in this article are positive in the
transmission disequilibrium test (ﬁgure 3).
The impact of non-inherited factors on the course of CF
disease, and moreover the change of these confounders
over time, challenges classical strategies to validate ﬁndings of
association studies. Ideally, replication studies with large sample
sizes are used to verify ﬁndings. However, large CF patient
samples are likely to be heterogeneous and thus will not share
the major environmental determinants of CF disease progres-
sion. Taking this into account, we chose to replicate the ﬁndings
of our association study using conﬁrmatory CF endophenotypes
and within-dataset validation strategies. No evidence for the role
of the gene as a CF modiﬁer was found for six loci. Isolated
ﬁndingsddeﬁned as an association to only disease severity or
only a basic defect phenotypedwere observed for 20 genes. The
remaining 26 loci analysed in this study are positive for both, an
association with a clinical phenotype and a CF basic defect
phenotype (see ﬁgure 3 and supplemental table 8). As the basic
defect in CF is correlated with disease severity
11 these consistent
ﬁndings must be interpreted with caution with respect to the
underlying causality. Either the gene analysed has a direct
inﬂuence on the efﬁciency of F508del-CFTR processing and
trafﬁcking and thus causes a better phenotype; or alternatively,
the patient subsamples analysed for CFTR mediated residual
current in ICM or NPD can be considered as enriched with
individuals who are mildly diseased due to the association of
mild disease with residual function in respiratory and intestinal
tissue.
11 In the latter case, the ﬁndings of the association study
do not necessarily imply a direct causal action of the analysed
modiﬁer on the CF basic defect, but can be interpreted as
a supporting ﬁnding in two independent patient subsamples. As
an example, the mild TNFR haplotype (allele 1-10-2-2 at
markers rs767455, D12S889, rs1800692 and rs1800693)
18 is
signiﬁcantly enriched on transmitted chromosomes in the entire
European CF sibling population as indicated by TDT (Stanke
et al,
18 ﬁgure 3) and is associated with the concordant mildly
affected phenotype (Stanke et al,
18 ﬁgure 3) as well as with
residual chloride secretion of the nasal epithelium (ﬁgure 4). As
a causal interpretation, this might reﬂect the interaction of the
cytokine pathway and ion secretory properties of the
epithelium,
38e41 promoting residual chloride secretion among
carriers of the mild TNFR allele. Alternatively, as we observed
residual chloride secretion more frequently among patients with
mild disease phenotype,
11 the TNFR association with the basic
defect phenotype might reﬂect an overrepresentation of mild
modiﬁer alleles in this patient subgroup, which is equivalent to
a replication study with conﬁrmatory outcome.
In conclusion, describing modiﬁers in cystic ﬁbrosis remains
challenging even though the underlying disease is monogenic by
deﬁnition. In contrast, the manifestation of endophenotypes
such as diabetes, the CF basic defect and ultimately disease
severity is most likely polygenic by nature, implying that when
looking for CF modiﬁers, the same obstacles will be encountered
as in complex diseases such as asthma or cardiovascular disor-
ders. Based on our experience, we suggest that patient samples
in which individuals share as many non-inherited characteristics
as possible, and genetic markers which are selected for a high
information content to overcome the loss of power in small
sized study cohorts, will facilitate mapping of clinically mean-
ingful CF modiﬁers in the future.
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